Ziftomenib

Ziftomenib

Definition

An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.

Also known as KO 539, KO-539, KO539, Komzifti, Menin-KMT2A Inhibitor KO 539, Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor KO 539, Menin-MLL Inhibitor KO-539, Menin-MLL Interaction Inhibitor KO 539, ZIFTOMENIB — per NCIT

Also identified as

Indications

Disease Relation Source
Acute myeloid leukemia may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Bone marrow may treat a disease of this organ DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.